Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus

Neoplasia

Volumn 14, Issue 1, 2012, Pages 29-33

  Zhai, Rihong ^a   Zhao, Yang ^a   Su, Li ^a   Cassidy, Lauren ^a   Liu, Geoffrey ^b   Christiani, David C ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; BARRETT ESOPHAGUS; CELL FREE SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA DETERMINATION; DNA METHYLATION; EPIGENETICS; ESOPHAGEAL ADENOCARCINOMA; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE LOCUS; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; PILOT STUDY; PRIORITY JOURNAL; SERUM;

EID: 84863045726     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111626     Document Type: Article

References (44)

1. Jones PA and Baylin SB (2007). The epigenomics of cancer. Cell 128, 683-692.
2. Selaru FM, David S, Meltzer SJ, and Hamilton JP (2009). Epigenetic events in gastrointestinal cancer. Am J Gastroenterol 104, 1910-1912.
3. Esteller M (2008). Epigenetics in cancer. N Engl J Med 358, 1148-1159.
4. Jin Z, Cheng Y, Gu W, Zheng Y, Sato F, Mori Y, Olaru AV, Paun BC, Yang J, Kan T, et al. (2009). A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res 69, 4112-4115.
5. Schulmann K, Sterian A, Berki A, Yin J, Sato F, Xu Y, Olaru A, Wang S, Mori Y, Deacu E, et al. (2005). Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24, 4138-4148.
6. Wang JS, Guo M, Montgomery EA, Thompson RE, Cosby H, Hicks L, Wang S, Herman JG, and Canto MI (2009). DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's sophagus. Am J Gastroenterol 104, 2153-2160.
7. Arai E, Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, et al. (2009). Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome. Carcinogenesis 30, 214-221.
8. Arai E, Ushijima S, Gotoh M, Ojima H, Kosuge T, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, et al. (2009). Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma. Int J Cancer 125, 2854-2862.
9. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, Crowell RE, Karp DD, Stidley CA, and Picchi MA (2005). Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 11, 6505-6511.
10. Hoque MO, Begum S, Topaloglu O, Chatterjee A, Rosenbaum E, van Criekinge W, Westra WH, Schoenberg M, Zahurak M, Goodman SN, et al. (2006). Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 98, 996-1004.
11. Shapiro B, Chakrabarty M, Cohn EM, and Leon SA (1983). Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer 51, 2116-2120.
12. Leon SA, Shapiro B, Sklaroff DM, and Yaros MJ (1977). Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37, 646-650.
13. Levenson VV (2010). DNA methylation as a universal biomarker. Expert Rev Mol Diagn 10, 481-488.
14. Pinzani P, Salvianti F, Pazzagli M, and Orlando C (2010). Circulating nucleic acids in cancer and pregnancy. Methods 50, 302-307.
15. Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XO, Stroun M, Mulcahy HE, and Farthing MJ (1997). K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology 112, 1114-1120.
16. Mulcahy HE, Lyautey J, Lederrey C, Chen XQ, Lefort F, Vasioukhin V, Anker P, Alstead EM, Farthing M, and Stroun M (2000). Plasma DNA K-ras mutations in patients with gastrointestinal malignancies. Ann N Y Acad Sci 906, 25-28.
17. Beau-Faller M, Gaub MP, Schneider A, Ducrocq X, Massard G, Gasser B, Chenard MP, Kessler R, Anker P, Stroun M, et al. (2003). Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 105, 361-370.
18. Sanchez-Cespedes M, Monzo M, Rosell R, Pifarre A, Calvo R, Lopez-Cabrerizo MP, and Astudillo J (1998). Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients. Ann Oncol 9, 113-116.
19. Board RE, Knight L, Greystoke A, Blackhall FH, Hughes A, Dive C, and Ranson M (2008). DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomark Insights 2, 307-319.
20. Gormally E, Caboux E, Vineis P, and Hainaut P (2007). Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635, 105-117.
21. Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W, Rotmensch J, Kamat A, Sood AK, and Levenson V (2011). Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol Oncol 120, 113-120.
22. Liggett TE, Melnikov AA, Marks JR, and Levenson VV (2011). Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer 128, 492-499.
23. Lee BB, Lee EJ, Jung EH, Chun HK, Chang DK, Song SY, Park J, and Kim DH (2009). Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 15, 6185-6191.
24. Melnikov AA, Scholtens D, Talamonti MS, Bentrem DJ, and Levenson VV (2009). Methylation profile of circulating plasma DNA in patients with pancreatic cancer. J Surg Oncol 99, 119-122.
25. Iyer P, Zekri AR, Hung CW, Schiefelbein E, Ismail K, Hablas A, Seifeldin IA, and Soliman AS (2010). Concordance ofDNA methylation pattern in plasma and tumor DNA of Egyptian hepatocellular carcinoma patients. Exp Mol Pathol 88, 107-111.
26. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer DG, et al. (2000). Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 92, 1805-1811.
27. Usadel H, Brabender J, Danenberg KD, Jeronimo C, Harden S, Engles J, Danenberg PV, Yang S, and Sidransky D (2002). Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 62, 371-375.
28. Bradbury PA, Zhai R, Hopkins J, Kulke MH, Heist RS, Singh S, Zhou W, Ma C, Xu W, Asomaning K, et al. (2009). Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis 30, 793-798.
29. Zhai R, Chen F, Liu G, Su L, Kulke MH, Asomaning K, Lin X, Heist RS, Nishioka NS, Sheu CC, et al. (2010). Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol 28, 2445-2451.
30. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, Mclaughlin JK, and Nyren O (2004). Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 96, 388-396.
31. Thirlwell C, Eymard M, Feber A, Teschendorff A, Pearce K, Lechner M, Widschwendter M, and Beck S (2010). Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. Methods 52, 248-254.
32. Lleras RA, Adrien LR, Smith RV, Brown B, Jivraj N, Keller C, Sarta C, Schlecht NF, Harris TM, Childs G, et al. (2011). Hypermethylation of a cluster of kruppel-type zinc finger protein genes on chromosome 19q13 in oropharyngeal squamous cell carcinoma. Am J Pathol 178, 1965-1974.
33. Barrett MT, Yeung KY, Ruzzo WL, Hsu L, Blount PL, Sullivan R, Zarbl H, Delrow J, Rabinvitch PS, and Reid BJ (2002). Transcriptional analyses of Barrett's metaplasia and normal upper GI mucosae. Neoplasia 4, 121-128.
34. van Baal JW, Milano F, Rygiel AM, Bergman JJ, Rosmolen WD, van Deventer SJ, Wang KK, Peppelenbosch MP, and Krishnadath KK (2005). A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology 129, 1274-1281.
35. Bauerschlag DO, Ammerpohl O, Brautigam K, Schem C, Lin Q, Weigel MT, Hilpert F, Arnold N, Maass N, Meinhold-Heerlein I, et al. (2011). Progressionfree survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology 80, 12-20.
36. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, Teo WW, Zhang Z, Huang P, Visvananthan K, et al. (2011). Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res 71, 6195-6207.
37. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, Peehl DM, Brooks JD, Myers RM, and Sherlock G (2011). DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 21, 1017-1027.
38. Starker LF, Svedlund J, Udelsman R, Dralle H, Akerstrom G, Westin G, Lifton RP, Bjorklund P, and Carling T (2011). The DNAmethylome of benign andmalignant parathyroid tumors. Genes Chromosomes Cancer 50, 735-745.
39. Zou H, Molina JR, Harrington JJ, Osborn NK, Klatt KK, Romero Y, Burgart LJ, and Ahquist DA (2005). Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 116, 584-591.
40. Zou H, Osborn NK, Harrington JJ, Klatt KK, Molina JR, Burgart LJ, and Ahquist DA (2005). Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 14, 830-834.
41. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA, et al. (2001). Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61, 3410-3418.
42. Sato F, Jin Z, Schulmann K, Wang J, Greenwald BD, Ito T, Kan T, Hamilton JP, Yang J, Paun B, et al. (2008). Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One 3, e1890.
43. Levenson VV and Melnikov AA (2011). The MethDet: a technology for biomarker development. Expert Rev Mol Diagn 11, 807-812.
44. Campan M, Weisenberger DJ, Trinh B, and Laird PW (2009). MethyLight. Methods Mol Biol 507, 325-337.